{"schema_version":"secwatch.filing_event.v1","accession":"0001140361-26-020402","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2026-05-11T13:20:50+00:00","discovered_at":"2026-05-11T14:49:57.127956+00:00","generated_at":"2026-05-11T18:09:00.921848+00:00","sec_items":["2.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Aurinia completes acquisition of Kezar Life Sciences for $6.955/share plus CVR","bullets":["Offer price: $6.955 cash per share plus one contingent value right (CVR).","5,927,580 shares tendered (~80.24% of outstanding) as of Expiration Time on May 8, 2026.","Merger completed on May 11, 2026 under DGCL Section 251(h); no stockholder vote required.","Outstanding in-the-money options converted to cash spread plus CVRs; out-of-the-money options cancelled.","CVR Agreement dated May 11, 2026 with Broadridge as Rights Agent and Fortis Advisors as Representative."],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-020402","json":"https://secwatch.observer/filing/0001140361-26-020402.json","markdown":"https://secwatch.observer/filing/0001140361-26-020402.md","text":"https://secwatch.observer/filing/0001140361-26-020402.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/0001140361-26-020402-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/ef20072568_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-11T18:09:00.921848+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7ff094a1ae8dffdf43e86f1e08ead0a58be6ac7f","claim":"Aurinia Pharmaceuticals Inc. completed an acquisition involving Kezar Life Sciences, Inc. for $6.955 in cash, plus one contingent value right (closed 2026-05-11).","evidence_excerpt":"On May 8, 2026, Parent completed a tender offer for (i) the acquisition of all of the Company’s outstanding shares of common stock, par value $0.001 per share (the “Common Stock”), by Parent through a tender offer (the “Offer”) for a price per share of the Common Stock of: (A) $6.955 in cash (the “Cash Amount”), payable without interest, plus (B) one contingent value right (a “CVR”) (together with the Cash Amount, the “Offer Price”); and (ii) the merger of Merger Sub with and into the Company (the “Merger”), with the Company surviving the Merger.","evidence_source":"SEC 8-K Item 2.01/5.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1600620/000114036126020402/0001140361-26-020402-index.htm","confidence":0.9,"family_label":"M&A Transactions","details":[{"label":"Action","value":"acquisition"},{"label":"Counterparty","value":"Kezar Life Sciences, Inc."},{"label":"Consideration","value":"$6.955 in cash, plus one contingent value right"},{"label":"Closing","value":"2026-05-11"}],"fact_type":"ma_transaction"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}